Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmacia leridistim

Executive Summary

Company discontinues Phase III trial of leridistim for the treatment of complications associated with chemotherapy treatment. The hematopoietic growth factor promoted neutrophil recovery after chemotherapy at least as well as the comparator did, but the primary endpoint of febrile neutropenia was confounded on the leridistim arm by drug-related side effect of fever. The fever led to a higher rate of febrile neutropenia in the leridistim group
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS036384

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel